GO:0046103 inosine biosynthetic process: Nucleoside Metabolism Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046103 (inosine biosynthetic process) describes the chemical reactions and pathways that form inosine, the hypoxanthine riboside nucleoside.
• Inosine is generated both by de novo purine biosynthesis and by adenosine-to-inosine (A-to-I) RNA editing, which is catalyzed by ADAR enzymes.
• A-to-I editing and inosine formation are central to distinguishing self from non-self RNA and to innate immune tolerance.
• Inosine biosynthetic capacity influences hematopoiesis, metabolic energy expenditure, and neuronal function.
• Dysregulated inosine metabolism is linked to cancer, autoinflammatory disease, and neurological disorders.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of inosine pathway genes.
Description
GO:0046103, inosine biosynthetic process, is the biological process comprising the chemical reactions and pathways that result in the formation of inosine, hypoxanthine riboside, a nucleoside found free but not in combination in nucleic acids except in the anticodons of some tRNAs. Inosine is a pivotal metabolite and a non-canonical nucleoside that arises through multiple routes, including de novo purine biosynthesis and the hydrolytic deamination of adenosine within RNA by adenosine deaminases acting on RNA (ADARs). Because inosine is read as guanosine by the translational machinery, its production via A-to-I editing expands the informational content of the transcriptome and is essential for normal physiology. Researchers study this process because inosine and its editing-derived signatures are increasingly recognized as regulators of immunity, metabolism, and cell fate. The formation of inosine is not merely a metabolic endpoint but a signaling and regulatory event: extracellular inosine can act as a purinergic ligand that promotes energy expenditure in adipose tissue, while intracellular inosine patterns mark RNA as self and prevent inappropriate innate immune activation. Consequently, the enzymes and pathways that produce inosine are attractive targets for understanding disease mechanisms and for developing therapeutic interventions. This article synthesizes authoritative GO annotation and verified literature to provide a research-grade overview of GO:0046103, its genes, regulation, disease links, and the CRISPR-based methods used to study it.
inosine biosynthetic process At A Glance
| GO ID | GO:0046103 |
|---|---|
| GO term | inosine biosynthetic process |
| Ontology | biological_process |
| Synonym | inosine anabolism; inosine biosynthesis; inosine formation; inosine synthesis |
| Major function | Formation of inosine via purine biosynthesis and A-to-I RNA editing |
| Definition source | QuickGO definition: chemical reactions and pathways resulting in the formation of inosine, hypoxanthine riboside |
| Related enzymes | ADAR1 (ADAR), ADAR2 (ADARB1), purine biosynthetic enzymes |
| Related diseases | Cancer, autoinflammatory disease, neurological disorders |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, RNA-seq, Ribo-seq, metabolomics |
What Is GO:0046103?
In our own words, GO:0046103 (inosine biosynthetic process) encompasses the enzymatic steps and metabolic routes that synthesize inosine, a purine nucleoside composed of hypoxanthine linked to ribose. The process includes both the de novo purine biosynthetic branch that yields inosine monophosphate (IMP) and its dephosphorylation to inosine, as well as the generation of inosine within RNA through adenosine deamination by ADAR enzymes. The term is a biological process and is distinct from inosine catabolism or salvage; it specifically covers formation of the free nucleoside and editing-derived inosine.
Why Is inosine biosynthetic process Important in Cell Biology?
GO:0046103 is important because inosine is both a metabolic intermediate and a regulatory molecule whose production shapes transcriptome diversity, immune tolerance, and cellular energy balance. A-to-I editing, which generates inosine in RNA, is essential for distinguishing self from non-self RNA and for preventing aberrant innate immune activation. Inosine also functions as an extracellular signal that can enhance energy expenditure in brown adipose tissue. Disruption of inosine biosynthetic pathways is associated with hematological abnormalities, cancer progression, and neurological disease, making this process a high-value area for mechanistic and translational research.
• Inosine is a key product of A-to-I RNA editing, which diversifies the transcriptome and proteome.
• ADAR1-mediated inosine formation is required to prevent innate immune sensing of self RNA.
• Editing-specific inosine patterns help the immune system distinguish self from non-self RNA.
• Inosine biosynthetic capacity influences hematopoietic stem and progenitor cell function.
• Extracellular inosine promotes energy expenditure via brown adipocytes.
• Dysregulated inosine metabolism is implicated in cancer and autoimmune conditions.
• Inosine is a biomarker and potential therapeutic target in neurological disorders.
• CRISPR models enable causal testing of inosine pathway genes in disease contexts.
• Inosine formation intersects with purine metabolism and nucleotide homeostasis.
• Understanding GO:0046103 supports development of RNA-editing-based therapeutics.
What Happens During inosine biosynthetic process?
De novo purine biosynthesis and IMP formation
In simple terms: The cell builds a purine ring from scratch to make inosine monophosphate, the precursor of inosine.
Inosine biosynthesis begins with the de novo purine pathway, which assembles the purine ring onto ribose-5-phosphate to produce inosine monophosphate (IMP). IMP is the branch-point metabolite that can be converted to AMP or GMP, or dephosphorylated to inosine. This pathway is fundamental to nucleotide supply and is conserved across eukaryotes. The GO term GO:0046103 captures the reactions that lead to inosine formation, including this de novo route.
Adenosine-to-inosine RNA editing by ADAR enzymes
In simple terms: Enzymes called ADARs chemically change adenosine letters in RNA into inosine letters.
A major route to inosine is the hydrolytic deamination of adenosine to inosine within RNA, catalyzed by adenosine deaminases acting on RNA (ADAR1 and ADAR2). This A-to-I editing event is essential for normal transcriptome function and is a principal source of inosine in cells. ADAR1 is particularly important for editing endogenous double-stranded RNA and for preventing innate immune activation. The resulting inosine is read as guanosine during translation, effectively recoding the RNA.
Editing-specific inosine patterns and self/non-self discrimination
In simple terms: The pattern of inosine marks in RNA acts like a molecular ID that tells the immune system the RNA belongs to the body.
Recent work shows that editing-specific inosine patterns are used to distinguish self from non-self RNA. This discrimination is critical for avoiding autoinflammatory responses. ADAR1 loss leads to accumulation of unedited self RNA that triggers innate immune sensors. Thus, inosine biosynthesis via editing is not only a coding event but also an immune tolerance mechanism.
Inosine as an extracellular signaling molecule
In simple terms: Inosine can leave cells and act as a signal that changes how other cells behave.
Beyond its intracellular roles, inosine is released extracellularly and can act as a purinergic signaling molecule. Apoptotic brown adipocytes release inosine, which enhances energy expenditure in surrounding tissue. This demonstrates that inosine biosynthetic output can have systemic metabolic effects. The GO term encompasses the formation of inosine that feeds into these signaling pools.
Integration with purine salvage and nucleotide pools
In simple terms: Inosine sits at a crossroads where it can be recycled or used to build other nucleotides.
Inosine formed through biosynthesis can be salvaged or interconverted to support nucleotide pools. This integration ensures balanced purine availability for DNA and RNA synthesis. Dysregulation of these fluxes can affect cell proliferation and survival, linking GO:0046103 to cancer and metabolic disease.
Key Genes Involved in GO:0046103 inosine biosynthetic process
The following genes and proteins are central to inosine biosynthetic process (GO:0046103) and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADAR | Adenosine deaminase acting on RNA 1; edits adenosine to inosine in dsRNA | Innate immunity, autoinflammation, cancer |
| ADARB1 | Adenosine deaminase acting on RNA 2; edits specific neuronal transcripts | Neuronal function, editing recoding |
| ADARB2 | ADAR family member with editing-related functions | RNA editing biology |
| ATIC | Bifunctional purine biosynthesis enzyme (IMP cyclohydrolase) | De novo purine pathway |
| GART | Phosphoribosylglycinamide formyltransferase | Purine biosynthesis |
| PAICS | Phosphoribosylaminoimidazole carboxylase | Purine biosynthesis |
| PPAT | Phosphoribosyl pyrophosphate amidotransferase | First committed step of purine synthesis |
| IMPDH1 | Inosine monophosphate dehydrogenase 1 | IMP to GMP flux |
| IMPDH2 | Inosine monophosphate dehydrogenase 2 | Nucleotide balance, cancer |
| HPRT1 | Hypoxanthine phosphoribosyltransferase 1 | Purine salvage |
| PNP | Purine nucleoside phosphorylase | Inosine catabolism/salvage |
| ADA | Adenosine deaminase | Adenosine/inosine metabolism |
| ENT1 (SLC29A1) | Equilibrative nucleoside transporter 1 | Inosine transport |
| ENT2 (SLC29A2) | Equilibrative nucleoside transporter 2 | Nucleoside uptake |
| ADORA2A | Adenosine A2A receptor | Purinergic signaling |
| ADORA2B | Adenosine A2B receptor | Inosine signaling |
| NT5C2 | Cytosolic 5'-nucleotidase II | IMP dephosphorylation to inosine |
| NT5C3A | Cytosolic 5'-nucleotidase III | Nucleoside formation |
How Is inosine biosynthetic process Regulated?
Inosine biosynthetic process is regulated at multiple levels. ADAR1 expression and activity are controlled by interferon signaling, linking editing to immune status. ADAR2 activity is modulated by its own editing and by neuronal activity. Purine biosynthetic enzymes are regulated by feedback inhibition by purine nucleotides and by transcriptional programs that respond to growth signals. Extracellular inosine levels are influenced by nucleoside transporters and by the release of inosine from apoptotic cells. Together, these layers ensure that inosine production is matched to cellular demand and immune context.
inosine biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADAR | Autoinflammatory disease, innate immune activation | ADAR KO and point-mutation cell lines |
| ADARB1 | Neurological disorders, epilepsy | ADARB1 KO neurons |
| IMPDH2 | Cancer proliferation | IMPDH2 knockout cancer cells |
| ADA | Severe combined immunodeficiency | ADA knockout hematopoietic cells |
| PNP | Immunodeficiency | PNP knockout models |
Inosine biosynthesis and autoinflammatory disease
Loss of ADAR1-mediated inosine formation causes accumulation of unedited self RNA, which triggers innate immune sensors and leads to autoinflammatory pathology. Editing-specific inosine patterns are essential for self/non-self discrimination, and their disruption is linked to interferonopathies. This makes GO:0046103 a key process in immune tolerance.
Inosine biosynthesis in cancer
Altered purine metabolism and A-to-I editing are observed in multiple cancers. Inosine monophosphate dehydrogenase (IMPDH) activity supports nucleotide supply for proliferation, and editing changes can affect oncogene and tumor suppressor transcripts. Targeting inosine biosynthetic enzymes is being explored as a therapeutic strategy.
Inosine biosynthesis in neurological disorders
ADAR2-mediated editing of neuronal transcripts is critical for normal brain function, and dysregulated editing has been implicated in epilepsy and neurodegeneration. Inosine and its derivatives are also studied as neuroprotective agents. These findings connect GO:0046103 to neurological disease mechanisms.
Inosine biosynthesis and metabolic disease
Extracellular inosine released from apoptotic brown adipocytes enhances energy expenditure, linking inosine production to metabolic homeostasis. This suggests that inosine biosynthetic pathways may be relevant to obesity and metabolic disorders.
From inosine biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ADAR1 alter inosine levels and immune activation? | ADAR1 knockout cell line |
| Does a specific editing site require ADAR2? | ADAR2 point-mutation knock-in |
| Can inosine production be monitored in live cells? | Tagged knock-in of ADAR or reporter |
| Does overexpression of IMPDH increase inosine flux? | IMPDH overexpression cell model |
| Does inosine release affect adipocyte energy expenditure? | Brown adipocyte knockout/overexpression |
| Does inosine biosynthetic gene loss affect hematopoiesis? | CRISPR knockout in hematopoietic stem cells |
How to Study the inosine biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcript abundance and A-to-I editing sites | Global editing profiling |
| LC-MS metabolomics | Inosine and purine metabolite levels | Quantify biosynthetic flux |
| Ribo-seq | Ribosome occupancy and recoding | Translational impact of inosine |
| CRISPR knockout | Gene function loss | Causal testing of pathway genes |
| CRISPR point mutation | Specific amino acid or regulatory site | Dissect enzyme activity |
| Knock-in reporter | Real-time inosine production | Live-cell imaging |
| Bioinformatics pipeline | Editing site prediction and enrichment | Identify inosine signatures |
RNA sequencing and editing detection
RNA-seq followed by bioinformatic detection of A-to-I editing sites is the primary method to quantify inosine formation in transcripts. Editing-specific inosine patterns can be identified by comparing genomic and cDNA sequences. This approach reveals global editing landscapes and site-specific changes.
Metabolomics and nucleoside quantification
Liquid chromatography-mass spectrometry (LC-MS) can directly measure inosine and related purine metabolites in cells and tissues. This provides a quantitative readout of inosine biosynthetic flux.
Ribo-seq and translation profiling
Ribo-seq measures ribosome occupancy and can reveal the translational consequences of inosine recoding in mRNA. It is used to determine how editing-derived inosine changes protein output.
CRISPR-based functional genomics
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes in the inosine biosynthetic pathway. Pooled library screening can identify modifiers of inosine levels and editing.
How CRISPR Can Be Used to Study GO:0046103 inosine biosynthetic process
Knockout
CRISPR knockout of ADAR, ADARB1, or purine biosynthetic genes eliminates inosine production and reveals downstream phenotypes such as immune activation or metabolic changes. Knockout models are essential for establishing causality in GO:0046103.
Point Mutation
Point mutations can be introduced into catalytic residues of ADAR enzymes to separate editing activity from other functions. This allows precise structure-function analysis of inosine biosynthesis.
Knock-in
Knock-in of tagged ADAR or reporter constructs enables tracking of inosine formation in live cells. Knock-in of disease-associated variants can model human mutations affecting inosine pathways.
Overexpression
Overexpression of ADAR or IMPDH increases inosine production and can be used to study gain-of-function effects in cancer and metabolism. Overexpression models complement loss-of-function studies.
How EDITGENE Supports inosine biosynthetic process Research
Researchers studying inosine biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in inosine production, editing, or downstream phenotypes. EDITGENE provides the full suite of CRISPR cell model services to enable such causal experiments.
Contact EDITGENE today to design your custom CRISPR model for inosine biosynthetic process research.
Frequently Asked Questions About inosine biosynthetic process
What is inosine biosynthetic process?
It is the biological process GO:0046103 that comprises the chemical reactions and pathways forming inosine, a purine nucleoside.
What genes are involved in inosine biosynthetic process?
Key genes include ADAR, ADARB1, IMPDH1, IMPDH2, ATIC, GART, PAICS, and PPAT.
How is inosine made in cells?
Inosine is made via de novo purine biosynthesis and by ADAR-mediated deamination of adenosine in RNA.
What is the role of ADAR1 in inosine formation?
ADAR1 edits adenosine to inosine in double-stranded RNA and is essential for preventing innate immune activation.
Why is inosine important for immunity?
Editing-specific inosine patterns help distinguish self from non-self RNA and maintain immune tolerance.
Can inosine act as a signaling molecule?
Yes, extracellular inosine released from apoptotic brown adipocytes enhances energy expenditure.
What diseases are linked to inosine biosynthesis?
Autoinflammatory disease, cancer, neurological disorders, and metabolic disease have been linked to inosine pathways.
How do researchers study inosine biosynthetic process?
They use RNA-seq, LC-MS metabolomics, Ribo-seq, and CRISPR models to measure inosine and editing.
What CRISPR models are used for inosine research?
Knockout, point mutation, knock-in, and overexpression models are used to test gene function.
Where can I get CRISPR cell models for inosine pathway genes?
EDITGENE provides knockout, point mutation, knock-in, overexpression, and library screening services for inosine research.
Conclusion
GO:0046103 (inosine biosynthetic process) is a central biological process that generates inosine through purine biosynthesis and A-to-I RNA editing. Its products influence immunity, metabolism, and neuronal function, and its dysregulation is linked to cancer, autoinflammation, and neurological disease. CRISPR-based models are indispensable for dissecting the causal roles of inosine pathway genes, and EDITGENE offers comprehensive services to support such research.
References
- 1. Niemann B et al.. 2022. Apoptotic brown adipocytes enhance energy expenditure via extracellular inosine.. Nature 609(7926):361-368 PMID: 35790189
- 2. Bass BL. 2024. Adenosine deaminases that act on RNA, then and now.. RNA 30(5):521-529 PMID: 38531651
- 3. Srinivasan S et al.. 2021. Inosine in Biology and Disease.. Genes (Basel) 12(4) PMID: 33921764
- 4. Mannion NM et al.. 2014. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA.. Cell Rep 9(4):1482-94 PMID: 25456137
- 5. Varada R et al.. 2026. Distinguishing self from non-self RNA by editing-specific inosine patterns.. Nucleic Acids Res 54(16) PMID: 42635125
- 6. Liang Z et al.. 2024. A-to-I RNA editing and hematopoiesis.. Exp Hematol 139:104621 PMID: 39187172
- 7. Zinshteyn B et al.. 2009. Adenosine-to-inosine RNA editing.. Wiley Interdiscip Rev Syst Biol Med 1(2):202-209 PMID: 20835992
- 8. Gatsiou A et al.. 2018. Adenosine-to-Inosine RNA Editing in Health and Disease.. Antioxid Redox Signal 29(9):846-863 PMID: 28762759
